Alzamend Neuro Inc. (ALZN) stock prices were down 2.61% around the time of market opening on September 1st, 2021. This brought the price per share up to USD$2.98 early on in the trading day.
ALZN Stock Partners with Altasciences
August 17th 2021 saw the early clinical-stage biopharmaceutical company announce its contract with Altasciences to conduct a six-month Phase 1 relative bioavailability study for AL001. The treatment is for Alzheimer’s patients and the study will commence in September 2021. The phase 1 first-in-human study is designed to determine the potentially clinically safe and appropriate dosing of AL001 in upcoming studies. ALZN stock’s AL001 is a lithium-delivering ionic cocrystal under development as an oral treatment for patients with dementia. These patients will report dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer’s disease.
Phase 1 Clinical Study
The company is bolstered by its recent partnership and its confidence in the successful execution of the joint Phase 1 clinical study. The treatment is believed to potentially provide clinicians with a significant improvement on current lithium-based treatments. AL001 could constitute a means of treating Alzheimer’s and other neurodegenerative diseases and psychiatric disorders.
ALZN Stock’s AL001
The Phase 1 study will serve to investigate the pharmacokinetics of lithium following a single dose of AL001. This will be compared to a typical single dose of a marketed 300 mg immediate-release lithium carbonate capsule. The study will be conducted in healthy male and female patients. Each patient will be administered approved amounts of the lithium and salicylate components of AL001. The study’s purpose will be to evaluate the safety, tolerability, and bioavailability of the study drug, as compared to currently marketed formulations of its comparator, lithium carbonate.
About ALZN
ALZN stock focuses on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease. The company continues to allocate resources toward the rapid development and safe marketing of effective treatments. The company’s existing product pipeline consists of AL001 and AL002. Both of these product candidates are licensed from the University of South Florida Research Foundation.
Future Outlook for ALZN Stock
The company reported a promising quarter, consolidated by the strength of its financial reports and topped off with its collaboration with Altasciences. ALZN stock is keen to leverage the combined resources at its disposal to usher in unprecedented growth. Investors are hopeful that this will translate into significant and sustained increases in shareholder value over the long term.
